GSK reports early trial results for Mo-Rez in ovarian and endometrial cancers
The Facts
- GSK reported early-stage clinical results for mocertatug rezetecan, also known as Mo-Rez, in gynecological cancers.
- In platinum-resistant ovarian cancer, Mo-Rez showed an objective response rate of 62% in the reported early data.
- In endometrial cancer, Mo-Rez showed an objective response rate of 67% in the reported early data.
- The reported response metric referred to patients whose tumors shrank by at least 30%, and in some coverage was described as tumors shrinking or disappearing.
- Mo-Rez is an antibody-drug conjugate, a type of targeted cancer therapy.
- GSK plans to move Mo-Rez into late-stage testing, with five phase 3 trials planned.
Context
What is Mo-Rez?
Mo-Rez is GSK's name for mocertatug rezetecan, an experimental antibody-drug conjugate being developed for cancers including ovarian and endometrial cancer London South East,Financial Times News.
What do the 62% and 67% results mean?
They refer to objective response rates in the early trial: the share of patients whose tumors met the study's threshold for a meaningful response, defined in Reuters and FT coverage as at least a 30% reduction in tumor size Yahoo! Finance,Financial Times News.
What happens next for the drug?
GSK said it plans to advance Mo-Rez into late-stage development, with five phase 3 trials planned this year Bloomberg Business,London South East,Financial Times News.
View all 16 sources
Wire services (4)
Independent coverage (12)
About these frames
See this differently than someone you know would? Two ways to keep it going.
The dial works on any URL — paste an article you read elsewhere this week.